已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

医学 无容量 头颈部鳞状细胞癌 内科学 肿瘤科 免疫疗法 肿瘤进展 头颈部癌 头颈部 外科 癌症
作者
Esma Saada‐Bouzid,Cécile Defaucheux,Andy Karabajakian,Virginia Palomar Coloma,Vincent Servois,Xavier Paolettí,Caroline Even,Jérôme Fayette,J. Guigay,Delphine Loirat,Frédéric Peyrade,Marie Alt,Jocelyn Gal,Christophe Le Tourneau
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:28 (7): 1605-1611 被引量:520
标识
DOI:10.1093/annonc/mdx178
摘要

Pembrolizumab and nivolumab are immune checkpoint inhibitors targeting PD-1 that have recently been approved in pretreated recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. In the clinic, some patients seem not only not to benefit from anti-PD-L1/PD-1 agents but rather to experience an acceleration of tumor growth kinetics (TGK).We retrospectively compared TGK on immunotherapy and TGK on last treatment in patients with R/M HNSCC treated with PD-1/PD-L1 inhibitors in four French centers. The TGK ratio (TGKR, ratio of the slope of tumor growth before treatment and the slope of tumor growth on treatment) was calculated. Hyperprogression was defined as a TGKR ≥ 2.From September 2012 to September 2015, 34 patients were identified. Patterns of recurrence included exclusive loco-regional recurrence in 14 patients, exclusive distant metastases in 11 patients, and both in 9 patients. No pseudo-progression was observed. Hyperprogression was observed in 10 patients (29%), including 9 patients with at least a locoregional recurrence, and only 1 patient with exclusively distant metastases. Hyperprogression significantly correlated with a regional recurrence (TGKR ≥ 2: 90% versus TGKR < 2: 37%, P = 0.008), but not with local or distant recurrence. Hyperprogression was associated with a shorter progression-free survival (PFS) according to RECIST (P = 0.003) and irRECIST (P = 0.02), but not with overall survival (P = 0.77).Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter PFS. It occurred in 39% of patients with at least a locoregional recurrence and 9% of patients with exclusively distant metastases. No pseudo-progressions were reported. Mechanisms and causality of hyperprogression should further be assessed through prospective controlled studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
闪闪书蕾发布了新的文献求助10
2秒前
迅速道之完成签到,获得积分10
2秒前
Essie发布了新的文献求助30
2秒前
思源的应助被xin采纳,获得10
3秒前
3秒前
4秒前
周白李许发布了新的文献求助10
4秒前
6秒前
鱼鱼发布了新的文献求助10
7秒前
科研通AI2S的应助被tomatoGG采纳,获得10
7秒前
吴丹完成签到,获得积分10
8秒前
suyi发布了新的文献求助30
9秒前
小林爱学习完成签到,获得积分20
9秒前
止境完成签到,获得积分10
9秒前
冷艳的紫发布了新的文献求助10
9秒前
胡高照发布了新的文献求助10
9秒前
汉堡包的应助被吃个橘子吧采纳,获得10
10秒前
10秒前
10秒前
天佑完成签到,获得积分20
10秒前
两颗牙发布了新的文献求助10
11秒前
zb123完成签到,获得积分10
11秒前
12秒前
FashionBoy的应助被失物爱采纳,获得10
13秒前
Hello的应助被失物爱采纳,获得10
13秒前
可爱的函函的应助被失物爱采纳,获得10
13秒前
13秒前
Ssssssinan的应助被失物爱采纳,获得10
13秒前
molihuakai的应助被cmx采纳,获得10
14秒前
15秒前
愤怒的书文完成签到 ,获得积分10
15秒前
浮云发布了新的文献求助10
16秒前
16秒前
16秒前
18秒前
情怀的应助被Ran采纳,获得10
19秒前
tomatoGG发布了新的文献求助10
19秒前
超级拖延症完成签到 ,获得积分10
19秒前
xin发布了新的文献求助10
20秒前
stella发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172444
求助须知:如何正确求助?哪些是违规求助? 9565203
关于积分的说明 21778439
捐赠科研通 7764184
什么是DOI,文献DOI怎么找? 3431343
关于科研通互助平台的介绍 2555224
邀请新用户注册赠送积分活动 2476362